Oncology Drug Reference Sheet: Nadofaragene Firadenovec-Vncg

Erin Dickman, MS, RN, OCN®
Voice

Description

Under the U.S. Food and Drug Administration’s (FDA’s) fast-track approval process, nadofaragene firadenovec-vncg (Adstiladrin®) became the first gene therapy approved for the treatment of high-risk non-muscle invasive bladder cancer. Approximately 75% of newly diagnosed bladder cancers are classified as non-muscle invasive. Bacillus Calmette Guérin (BCG) has been used as first-line therapy for more than 20 years, but eventually 30%–50% of patients stop responding, and nadofaragene firadenovec-vncg offers a new treatment option. FDA’s December 2022 approval was based on complete response (CR) and duration of response from Study CS-003, which demonstrated a 46% CR for at least one year.

View Article @ voice.ons.org

ONS Drug Education

Short summaries of newly approved oncology-related therapies or drugs with new indications.

View All Drug Education